Related studies have shown that, during adaptation to EGFR-TKIs (Gefitinib), certain NSCLC cell lines exhibit a significant increase in FGF2 and FGFR1 mRNA and protein levels. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.